Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

Joel W. Neal,Daniel B. Costa,Alona Muzikansky,Joseph B. Shrager,Michael Lanuti,James Huang, Kavitha J. Ramachandran,Deepa Rangachari,Mark S. Huberman,Zofia Piotrowska,Mark G. Kris,Christopher G. Azzoli,Lecia V. Sequist,Jamie E. Chaft

user-5f8cf9244c775ec6fa691c99（2021）

引用 5|浏览12

暂无评分

摘要

PURPOSEFor patients with surgically resected disease, multiple studies suggest a benefit of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in delaying cancer recurrence. ...

查看译文

关键词

Afatinib,Epidermal growth factor receptor,Lung cancer,Tyrosine kinase,Phases of clinical research,Cancer research,Adjuvant,Disease,Mutant,Medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要